MonoGen Announces First MonoPrep Customer Order

LINCOLNSHIRE, ILLINOIS, Jun 19 (MARKET WIRE) --
MonoGen, Inc. (TSX: MOG)(the "Corporation") today announced that it has
received its first customer purchase order for its flagship product, the
MonoPrep Processor.

"We are extremely pleased to announce this significant milestone for
MonoGen," said Jim Cureton, MonoGen's Vice President of Sales and
Marketing. "Our direct sales force calling on laboratories has generated
significant interest in MonoPrep and we are encouraged by the positive
response the sales team has received from our customers. It's clear that
the market sees the advantages of MonoPrep's unique design and the
improvements it brings to their current cytology operations. We look
forward to many more successes over the coming months as we ramp-up our
commercial launch activities."

About MonoGen, Inc.

MonoGen, Inc., headquartered in the Chicago area, is a medical device and
diagnostics company providing high-quality and cost-effective cytological
screening and diagnostic products to healthcare providers in the anatomic
pathology industry.

Forward-Looking Statements

This press release contains forward-looking statements. Statements
preceded by the words believe, expect, anticipate, plan, intend,
continue, estimate, may, will, and similar expressions are
forward-looking statements. Forward-looking statements are based on our
beliefs and assumptions based on information available at the time the
assumptions were made. Forward-looking statements relate to, among other
things, anticipated financial performance, business prospects,
strategies, regulatory developments, new services, market forces,
commitments and technological developments. By its nature, such
forward-looking information is subject to various risks and
uncertainties, which could cause our actual results to differ materially
from the anticipated results or other expectations expressed. Those risks
and uncertainties include, but are not limited to, our ability to raise
additional capital, our ability to execute our business plan while
maintaining at all times our various regulatory approvals, and the
response from existing and potential competitors. Additional discussions
of the various risks are contained in our Annual Information Form dated
March 19, 2008, which is available on SEDAR (www.sedar.com). Readers are
cautioned not to place undue reliance on this forward-looking
information, which is given as of the date it is expressed in this
document.

Contacts:
MonoGen, Inc.
Investor Relations
847-758-4284
847-758-9392 (FAX)
investorrelations@monogen.com

Copyright 2008, Market Wire, All rights reserved.

-0-